Immunis Named Among Top 25 Biotech & Life Sciences Companies for 2025 by The Healthcare Technology Report

Written by Emily J. Thompson, Senior Investment Analyst

Source: Businesswire

Updated: Aug 14 2025

0mins

Source: Businesswire

Immunis Recognition: Immunis, Inc. has been named one of the “Top 25 Biotech & Life Sciences Companies for 2025” by The Healthcare Technology Report, highlighting its innovative stem cell-derived therapy, IMM01-STEM, aimed at combating age-related muscle atrophy.
Company Overview: As a clinical-stage biotech firm, Immunis focuses on developing biologics from stem cell secretome technology to address immune dysregulation and age-related diseases, positioning itself as a leader in patient-centered biotechnology.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Immunis Named Among Top 25 Biotech & Life Sciences Companies for 2025 by The Healthcare Technology Report

About the author

Top News

Ford Announces $19.5B EV Restructuring Charges

Fed Cuts Interest Rates Amid Economic Concerns

SpaceX Targets $800 Billion Valuation in Secondary Sale

U.S. Consumer Sentiment Slightly Improves in December

Related Articles

Wallbridge Plans 25,000 Metres of Drilling in 2026 to Enhance Gold Project Value

TransAlta Receives 90-Day Operation Order from U.S. Department of Energy

People Also Watch